Digest Network Come funziona
Network
/
Società
Sc
Non verificato

Scribe Therapeutics Inc.

Di cosa scriviamo

BiotecnologiaCardiologiaEventiFarmaceuticaSalute

12 comunicati stampa

Guarda tutti i comunicati
17/11/2025
Scienza
Biotecnologia
Medicina - Varie
Cardiologia
Salute
Farmaceutica
Eventi
Fiere
Industria
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
Fonte
Scribe Therapeutics Inc.
Emittente
Business Wire
1.00
0
09/09/2025
Cardiologia
Biotecnologia
Tecnica
Salute
Farmaceutica
Scienza
Medicina - Varie
Eventi
Industria
Scribe Therapeutics Highlights Latest Data on Lp(a)-Lowering Therapy and Novel AI Platform for Next-Generation CRISPR-Based Therapeutics at Two Premier Conferences
Fonte
Scribe Therapeutics Inc.
Emittente
Business Wire
1.00
0
22/05/2025
Eventi
Industria
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Scribe Therapeutics Reports Positive Preclinical Data on its Novel CRISPR Technologies at the 2025 EAS Congress and ASGCT Annual Meeting
Fonte
Scribe Therapeutics Inc.
Emittente
Business Wire
1.00
0
05/05/2025
Industria
Biotecnologia
Salute
Farmaceutica
Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a Part of Lilly’s Gene Therapy Division
Fonte
Scribe Therapeutics Inc.
Emittente
Business Wire
1.00
0
23/04/2025
Eventi
Industria
Salute
Biotecnologia
Sanità
Farmaceutica
Cardiologia
Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress
Fonte
Scribe Therapeutics Inc.
Emittente
Business Wire
1.00
0
07/03/2025
Eventi
Industria
Biotecnologia
Salute
Cardiologia
Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference
Fonte
Scribe Therapeutics Inc.
Emittente
Business Wire
1.00
0
26/02/2025
Scienza
Biotecnologia
Farmaceutica
Salute
Sanità
Eventi
Scribe Therapeutics to Participate in Upcoming Conferences
Fonte
Scribe Therapeutics Inc.
Emittente
Business Wire
1.00
0
13/01/2025
Mercato del lavoro
Industria
Scienza
Biotecnologia
Medicina - Varie
Cardiologia
Salute
Farmaceutica
Oncologia
Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi
Fonte
Scribe Therapeutics Inc.
Emittente
Business Wire
1.00
0
09/01/2025
Finanza
Eventi
Fiere
Salute
Biotecnologia
Sanità
Farmaceutica
Scribe Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Fonte
Scribe Therapeutics Inc.
Emittente
Business Wire
1.00
0
25/11/2024
Eventi
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Cardiologia
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
Fonte
Scribe Therapeutics Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0